𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A partial model of the erythropoietin receptor complex

✍ Scribed by Caravella, Justin A.; Lyne, Paul D.; Richards, W. Graham


Publisher
John Wiley and Sons
Year
1996
Tongue
English
Weight
836 KB
Volume
24
Category
Article
ISSN
0887-3585

No coin nor oath required. For personal study only.

✦ Synopsis


A model of the structure of erythropoietin (Epo) is presented based on structural homology to other hemopoietic cytokines. A model of the erythropoietin receptor complex w a s made based on evidence that this includes a homodimer of the receptor chain with known sequence. Key interactions are noted which explain data from mutation experiments, although at not all residues believed to be important to binding of Epo are at the interface. This is consistent with the hypothesis that the Epo receptor complex includes proteins in addition to the cloned receptor chain that have been cross-linked to Epo (Todokoro et al., Proc.


πŸ“œ SIMILAR VOLUMES


Ambient error weighted partial least-squ
✍ Shizoom Wang; Timothy Larson πŸ“‚ Article πŸ“… 1993 πŸ› Elsevier Science 🌐 English βš– 464 KB

In the proposed model, both the amblent data and the source profiles were weqbted by the amblent mass scaled amblent error The comparison between thts model and the effectwe varrance we&ted chemtcal mass balance-type model was done usmg NBS test data sets The compared results show that the amblent e

Construction of the Simplest Model to Ex
✍ R.P. BYWATER; A. SØRENSEN; P. RØGEN; P.G. HJORTH πŸ“‚ Article πŸ“… 2002 πŸ› Elsevier Science 🌐 English βš– 178 KB

We study the mathematical solutions to the kinetic equations arising from various simple ligand-receptor [corrected] models. Focusing on the prediction of the various models for the activity vs. concentration curve, we find that solutions to the kinetic equations arising from the so-called dimer mod

Rational Design of Receptor Partial Agon
✍ Bao Ting Zhu πŸ“‚ Article πŸ“… 1996 πŸ› Elsevier Science 🌐 English βš– 397 KB

Partial activation of membrane receptors using specific partial agonists may be particularly beneficial to the treatment of some chronic diseases like congestive heart failure, because receptor partial activation usually avoids overstimulation and also minimizes desensitization. At present, partial